Select baseline characteristics
| Baseline characteristics | All treated patients (n=106) |
| Median age (range), years | 64.5 (40–84) |
| Sex, n (%) | |
| Male | 86 (81.1) |
| Female | 20 (18.9) |
| IMDC risk group, n (%) | |
| Favourable | 21 (19.8) |
| Intermediate | 65 (61.3) |
| Poor | 20 (18.9) |
| Race, n (%) | |
| White | 104 (98.1) |
| Black or African American | 1 (0.9) |
| Other | 1 (0.9) |
| KPS, n (%) | |
| 100 | 36 (34.0) |
| 90 | 45 (42.5) |
| 80 | 24 (22.6) |
| 70 | 1 (0.9) |
| Sarcomatoid features, n (%) | |
| Yes | 12 (11.3) |
| No | 93 (87.7) |
| Not reported | 1 (0.9) |
| Disease stage at study entry, n (%) | |
| III | 2 (1.9) |
| IV | 104 (98.1) |
| Number of disease sites, n (%) | |
| 1 | 5 (4.7) |
| ≥2 | 101 (95.3) |
| Most common sites of disease, n (%)* | |
| Visceral lung | 56 (52.8) |
| Lymph node | 43 (40.6) |
| Kidney | 41 (38.7) |
| Visceral liver | 26 (24.5) |
| Visceral adrenal | 16 (15.1) |
| Quantifiable tumour PD-L1 expression, n (%) | n=96 |
| <1% | 83 (86.5) |
| ≥1% | 13 (13.5) |
Information shown in the table is based on data collected using electronic case report forms.
*Patients may have more than one site.
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; KPS, Karnofsky performance status; PD-L1, programmed death ligand 1.